Novo to outsource R&D to India
Source: www.business-standard.com
It employs over 600 in the country and plans to triple its staff strength in 4 years.
Novo Nordisk, the $18.5 billion global leader in diabetes care, is planning to expand its drug discovery and manufacturing presence in India.
The company, which currently employs over 600 persons in India, will triple its staff strength in four years.
It is also firming up long term partnerships with Indian companies in key areas of drug discovery, financial management and sales, according to Melvin Oscar D’Souza, managing director, Novo Nordisk India.
“India will become the biggest market for diabetes care. Being the leaders in insulin business in the country and internationally, we have a lot of India specific growth plans”, D’Souza added.
The company, which has 60 per cent market share in the Rs 375 crore domestic insulin market, has tied up with the Ahmedabad-based Torrent Pharma to strengthen its manufacturing capabilities. Torrent, which maintains a dedicated insulin manufacturing facility exclusively for Novo Nordisk, is undergoing a major capacity expansion, D’Souza said.
Sanjeev M Shishoo, vice president (international operations) Novo Nordisk, said the company’s clinical trial operations are also likely to see a major expansion in the coming years.
“We have nine clinical trials in 65 centres across the country. About 600-650 patients will be screened as part of these trials”, Shishoo explained.
The company is also looking at outsourcing its data management requirements and financial services from Indian companies in the near future.
posted in Outsourcing News and Top Outsourcing deals, Outsourcing to India | 0 Comments







